Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in ...
Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by ...
VG081821AC is an adenosine A2A receptor (A2AR) antagonist that also acts as an inverse A2AR agonist. The trial is designed to assess the safety and efficacy of VG081821AC as a monotherapy ...